arrow
S

Shenglan Li

capital medical university
H指数:23
被引数:2,206

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bidirectional Causal Effect Between Gut Microbiota and Glioma Risk: A Systematic Review-Based Mendelian Randomization and Immune-Mediated Effect Analysis

肠道微生物组与胶质瘤风险之间的双向因果效应:一项基于系统综述的孟德尔随机化和免疫介导效应分析

2025-12-090
OAAI
The utility of ultra-deep RNA sequencing in Mendelian disorder diagnostics

超深度RNA测序在孟德尔疾病诊断中的应用价值

2025-10-100
PRE
SYHA1813, A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High-Grade Gliomas: A Multicenter, Open-Label Phase I Study

SYHA1813,一种VEGFR和CSF1R抑制剂,在复发高级别胶质瘤患者中的研究:一项多中心、开放标签的I期研究

2025-08-220
OAAI
Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory (R/R) Central Nervous System Lymphoma or Treatment-Naive (TN) Central Nervous System Lymphoma, Results from the Phase Ib Combination Part of HZ-a-018-102 Study

HZ-a-018研究(一项Bruton Tyrosine Kinase [BTK]抑制剂)在复发和/或难治性(R/R)中枢神经系统淋巴瘤或初治(TN)中枢神经系统淋巴瘤成年患者中的初步疗效与安全性:HZ-a-018-102研究Ib期联合治疗部分的结果

BLOOD
IF23.1
2024-11-050
PRE
The clinical utility and diagnostic implementation of human subject cell transdifferentiation followed by RNA sequencing
2024-05-014
PRE